CVS Health Corporation (NYSE: CVS) shares surged 5.11% in pre-market trading on Wednesday following the release of its third-quarter earnings report, which exceeded analyst expectations and prompted the company to raise its full-year guidance. The healthcare giant reported strong financial performance across its business segments, despite facing challenges in its Health Care Delivery unit.

For the third quarter, CVS Health posted adjusted earnings per share of $1.60, significantly surpassing the consensus estimate of $1.37. The company's revenue also beat expectations, coming in at $102.87 billion compared to the anticipated $98.85 billion. This robust performance led CVS to raise its full-year 2025 adjusted earnings per share guidance to a range of $6.55 to $6.65, up from the previous forecast of $6.30 to $6.40.

However, the positive results were tempered by a $5.7 billion goodwill impairment charge related to the company's Health Care Delivery reporting unit. CVS cited challenges impacting the unit's ability to grow at previously expected rates, leading to a decision to reduce the number of new primary care clinics it plans to open in 2026 and beyond. Despite this setback, investors appear to be focusing on the overall strength of CVS Health's core businesses and improved outlook, driving the stock's pre-market rally.